Condition

Oxytocin Deficiency

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 6 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials6

Recruiting2

Common interventions7

Lead sponsors shown4

Clinical trials

6 shown

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary DiseaseNCT07568509 · 2026-08-17

RECRUITING

Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy ControlsNCT06808516 · 2025-07-01

RECRUITING

Identifying Oxytocin Deficiency in Adults With Pituitary DiseaseNCT06460948 · 2024-11-13

COMPLETED

Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)NCT05319301 · 2022-04-01

COMPLETED

Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)NCT04897802 · 2021-09-13

COMPLETED

Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)NCT04902235 · 2021-07-06

COMPLETED

Common interventions

Control: Placebo administrationDRUG2 Norethindrone Acetate-Ethinyl EstradiolDRUG2 Experimental: CRH administrationDRUG1 Experimental: GLP1-RA (exenatide) administrationDRUG1 MelatoninDIETARY_SUPPLEMENT1 Oxytocin nasal sprayDRUG1 PlaceboDRUG1

Leading sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 3 Elizabeth Austen Lawson 1 Massachusetts General Hospital 1 University Hospital, Basel, Switzerland 1

Trial status mix

COMPLETED4

RECRUITING2

Phase mix

EARLY_PHASE12

PHASE42

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.